Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Biosimilars drove this increase with a 30% CER rise, while generics grew 2% CER. Core EBITDA for the second half was $40 million above consensus, with a full-year margin of 20.1%, exceeding the 19 ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar ... BIIB stock is up 0.19% at $140. ...

The Threads post’s assertion that stock image usage is evidence that the outbreak isn’t real misunderstands how photojournalism works. It also ignores the multiple public health departments and ...

Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number of FDA-approved biosimilars to 63. Forty-one of those biosimilars have ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit, filed ...

Biosimilars drove this increase with a 30% CER rise, while generics grew 2% CER. Core EBITDA for the second half was $40 million above consensus, with a full-year margin of 20.1%, exceeding the 19.7% ...